AIM ImmunoTech is trading 11% up today at $0.29 as the stock extends a sharp multi-day rebound driven by broader biotech sector strength and speculative interest.
- The move occurs alongside a 2% rise in the broader biotech sector, suggesting that sector-wide momentum and a shift toward higher-risk names are the primary drivers of the gain.
- There are no new company-specific filings, clinical readouts, or FDA decisions reported today to account for the continued recovery from recent lows below $0.25.